William Blair analyst Sami Corwin has maintained their bullish stance on PTCT stock, giving a Buy rating on April 22.
Sami Corwin has given his Buy rating due to a combination of factors surrounding PTC Therapeutics’ recent developments. The company has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, recommending conditional marketing authorization for Sephience (sepiapterin) in treating phenylketonuria (PKU). This recommendation includes a broad label covering all ages and severities of the disease, positioning Sephience for potential European approval and launch by mid-2025.
Moreover, the updated data from the Phase III APHENITY extension trial indicates significant patient benefits, with a majority able to liberalize their diet and increase protein intake. This data supports Sephience’s differentiated profile compared to existing treatments. The anticipated U.S. approval, aligned with the European progress, is expected to drive the stock’s performance in the coming year, reinforcing the Buy rating.
In another report released on April 22, RBC Capital also maintained a Buy rating on the stock with a $65.00 price target.